Furthermore, the employment of CAR-T cells targeting the transmembrane activator and calcium modulating ligand (CAML) interactor (TACI) offer a dual benefit since TACI is not only a myeloma target but is also expressed by Tregs [110]. The gene discussed is CAMLG; the disease is plasma cell myeloma.